HIV/AIDS in Georgia — Epidemiology and National Programme

HIV/AIDS epidemiology in Georgia: incidence, prevalence, key populations, national ART programme, testing policy and link to the hepatitis C elimination programme.

Regulations › Surveillance & Epidemiology

Type
Epidemiological Overview
Scope
Healthcare workers, public health professionals, researchers, international partners
Source
NCDC Georgia; IDACIRC; UNAIDS; ECDC
Publisher
PHIG Georgia
Updated
2025

Georgia has a concentrated HIV epidemic predominantly among people who inject drugs (PWID), men who have sex with men (MSM) and sex workers. While prevalence remains low in the general population, incidence has been rising in certain key populations. Georgia’s national HIV response is coordinated by the Infectious Diseases, AIDS and Clinical Immunology Research Centre (IDACIRC) with full ART access through the Universal Healthcare Programme.

~9,500people estimated to be living with HIV (about 0.3% of the population)Source: Tsertsvadze AIDS Center, 2025
560new HIV cases detected in 2023Source: AIDS Center, via JAMnews
6,900people receiving antiretroviral treatment (May 2025)Source: AIDS Center, via Georgia Today
Freeantiretroviral treatment, with universal access since 2004Source: Tsertsvadze AIDS Center, 2025

Epidemiological profile

IndicatorDataSource
People diagnosed with HIV since 198911,218 (as of 18 May 2025)AIDS Center, via Georgia Today
Estimated people living with HIV~9,500 (about 0.3% of the population)Tsertsvadze AIDS Center, 2025
Receiving antiretroviral treatment6,900 (May 2025)AIDS Center, via Georgia Today
New cases detected in 2023560AIDS Center, via JAMnews
Mode of transmission (cumulative)Heterosexual 53% · injecting drug use 30% · sex between men 14%AIDS Center, via Georgia Today
HIV prevalence in key populationsPeople who inject drugs 2.3% · men who have sex with men 16.2% · female sex workers 0.9%Tsertsvadze AIDS Center, 2025
Universal access to antiretroviral treatmentSince 2004Tsertsvadze AIDS Center, 2025

National HIV Programme — structure

  • Lead agency — Infectious Diseases, AIDS and Clinical Immunology Research Centre (IDACIRC), Tbilisi — national referral centre for HIV diagnosis, ART initiation and management
  • Coordination — MoLHSA and NCDC for policy, surveillance and international reporting; IDACIRC for clinical programme delivery
  • Funding — Global Fund to Fight AIDS, Tuberculosis and Malaria; Government of Georgia co-financing
  • ART access — All persons living with HIV in Georgia are entitled to free ART through the UHC programme; treatment initiated at IDACIRC and linked to regional clinics for follow-up
  • Testing — Voluntary confidential HIV testing available at IDACIRC, antenatal clinics, TB clinics, OST clinics and community-based organisations; rapid tests available for key populations; routine antenatal HIV screening
  • OST integration — HIV services are integrated with opioid substitution therapy (OST) programme for PWID; methadone and buprenorphine available nationwide

ART regimens — current first-line (Georgia)

PopulationPreferred first-line regimenNotes
Adults (treatment-naive)TLD: Tenofovir/Lamivudine/Dolutegravir (fixed-dose combination)WHO-recommended preferred regimen; high barrier to resistance; once-daily single tablet
Adults with TB co-infectionTLD with rifabutin substitution (rifampicin lowers dolutegravir levels); or TLD double-dose dolutegravir with rifampicinStart ART within 2 weeks if CD4 <50; within 8 weeks for others
Pregnant womenTLD (dolutegravir preferred in pregnancy per updated WHO 2021 guidance)Mandatory ART for PMTCT regardless of CD4; infant prophylaxis with NVP for 6 weeks
Children (<10 kg)Abacavir/Lamivudine/Lopinavir-ritonavir (age-appropriate formulation)Per WHO paediatric ART guidelines; managed at IDACIRC paediatric unit

HIV testing in healthcare settings

Key point

Provider-Initiated Testing and Counselling (PITC) — Georgian healthcare providers should offer HIV testing to: all pregnant women at first ANC visit; all TB patients; all patients with STIs; all patients presenting with conditions suggestive of HIV/AIDS (unexplained weight loss, recurrent infections, oral candidiasis, herpes zoster); all PWID entering healthcare settings; all persons diagnosed with hepatitis C. Refusal of testing must be documented. A reactive rapid HIV test must be confirmed by Western blot or a second different rapid test before disclosure of a positive result.

In plain language

Georgia has a low-prevalence HIV epidemic concentrated in key populations. Testing, antiretroviral treatment and prevention of mother-to-child transmission are free, and the country has maintained universal access to treatment since 2004. The main challenge is diagnosing people earlier.

Why it matters

~9,500people estimated to be living with HIV in Georgia (about 0.3% of the population)Source: Tsertsvadze Infectious Diseases, AIDS and Clinical Immunology Research Center, 2025
11,218people diagnosed with HIV in Georgia by 18 May 2025; 6,900 receiving antiretroviral treatmentSource: AIDS Center, via Georgia Today
2004since then Georgia has maintained universal access to antiretroviral treatment — the first country in Eastern Europe to do soSource: Tsertsvadze AIDS Center, 2025
Reported modes of HIV transmission, Georgia (% of cases)
Heterosexual contact53%
Injecting drug use30%
Sex between men14%
Source: AIDS Center data, via Georgia Today, May 2025

Key actions checklist

  • Offer HIV testing routinely where indicated, including to people with TB and hepatitis
  • Link everyone diagnosed to treatment without delay
  • Support adherence and viral load monitoring
  • Provide prevention services, including for key populations
  • Protect confidentiality in line with the patients’ rights law

International guidance

Questions and answers

Is HIV treatment free?

Yes, antiretroviral treatment is provided free of charge through the national programme.

What are the global targets?

UNAIDS 95-95-95: 95% of people with HIV diagnosed, 95% of them on treatment and 95% of those virally suppressed.

Georgian original source / ქართული წყარო

HIV/AIDS Surveillance and Programme — IDACIRC and NCDC Georgia

Open Georgian source →Additional reference →

NCDC publishes quarterly HIV situation reports. IDACIRC (idacirc.ge) manages the national ART programme.

PHIG Published by the Public Health Institute of Georgia (PHIG) · Regulations Hub · Contact PHIG